Conference Call with Gland Pharma Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Gland Pharma announced Q3FY25 results Revenue from operations: Rs 13841 million compared to Rs 15452 million during Q3FY24, change -10%. EBITDA: Rs 3,600 million compared to Rs 3,557 million during Q3FY24, change 1%. EBITDA margin: 26% for Q3FY25. PBT: Rs 2,993 million compared to Rs 2,832 million during Q3FY24, change 6%. PBT margin: 22% for Q3FY25. PAT: Rs 2,047 million compared to Rs 1,919 million during Q3FY24, change 7%. PAT margin: 15% for Q3FY25. Srinivas Sadu, Executive Chairman, Gland Pharma, said: “Our Q3FY25 revenue was at Rs 13,841 million. with an EBITDA of Rs 3,600 million., resulting in a 26% EBITDA margin. Notably, our base business EBITDA margin saw a significant improvement of 500 basis points, reaching 39%. We are also excited about the progress of our strategic biologics CDMO collaborations with some of the leading companies in this space. These partnerships open doors to exciting opportunities in the rapidly growing biologics CDMO segment and is expected to generate incremental revenue starting next financial year. Furthermore, the recent conclusion of the USFDA inspections at our Dundigal and Pashamylaram facilities underscores our unwavering commitment to quality and regulatory compliance. We remain focused on driving long-term value creation through strategic partnerships, innovation, and continued investments in new products and technologies." Shyamakant Giri, Chief Executive Officer, Gland Pharma, said: “I am honoured and excited to lead Gland Pharma as its new CEO. Building on the company's strong foundation, my focus will be on enhancing operational excellence in our base business, ensuring Cenexi's successful turnaround, identifying and pursuing new growth opportunities, and further solidifying our position as a leader in the CDMO space, particularly in biologics and complex injectables. I believe that by fostering a culture of innovation, collaboration, and customercentricity, we can achieve sustainable growth and create long-term value for all our stakeholders." Result PDF